Clin2
NCT04881682Possibly a fitRecruiting

Testing blood-cleansing vs immunoglobulin for CIDP

CIDP

Treatments studied

Part of Brain & nervous system, Immune system & allergy clinical trials.

This Phase 2 study compares a blood-cleansing treatment (immunoadsorption) with standard immune-boosting treatment (intravenous immunoglobulins) for chronic inflammatory demyelinating polyneuropathy (CIDP). It may help people whose steroid treatment did not work well, or who cannot take steroids.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
20 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have been diagnosed with CIDP (possible, probable, or definite), typical or atypical
  • You are 18 years or older
  • Your CIDP symptoms started less than or equal to 3 years ago
  • You previously tried methylprednisolone (a steroid) but it didn’t help enough, or you couldn’t take it due to side effects or reasons your doctor explains
  • You do not have a serious infection right now (blood test or urine test must be negative per the study)
  • You have no immune-related issue called IgA deficiency and no other reasons you can’t safely get the study treatments

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05584631Recruiting· Phase 1
Switching IVIG to weekly SCIG for CIDP treatment

This Phase 1 study compares IVIG given through an IV versus SCIG given under the skin, for people with CIDP. It aims to find the right weekly SCIG dose based on your current IVIG dose, which could make treatment more convenient.

New Brunswick, New Jersey
NCT06920004Recruiting· Phase 3
Testing empasiprubart vs IVIg for chronic CIDP

This study tests an investigational drug called empasiprubart against standard IVIg in adults with CIDP. The goal is to see if it is safer and more effective for people who still have symptoms despite IVIg therapy.

Birmingham, Alabama
NCT06714838Recruiting· Phase 3
Rituximab for remission in chronic inflammatory demyelinating polyneuropathy

This trial tests a drug called rituximab to see if it can help people with chronic inflammatory demyelinating polyneuropathy (CIDP) achieve remission. It may offer a new treatment option for those who are newly diagnosed or who are on maintenance therapy with wear-off symptoms or failed withdrawal attempts.

Amsterdam
NCT07719153Not yet recruiting
Ultrasound to guide treatment in chronic inflammatory neuropathy

This study uses ultrasound to see how nerve inflammation changes over time in people with a chronic nerve disease called CIDP. It may help doctors choose the best treatment. The trial includes both newly diagnosed patients and those whose current treatment isn't working well.

NCT07154524Recruiting
Immunoadsorption for CIDP treatment study

This trial tests whether a blood-filtering treatment called immunoadsorption can help people with CIDP. It is for adults who are already receiving or starting IVIg or MP therapy.

Ulm, Baden-Wurttemberg
NCT04589299Recruiting· Phase 4
Subcutaneous immune globulin for newly diagnosed CIDP

This study tests whether giving immune globulin under the skin (SCIG) can help people with newly diagnosed CIDP. It may help improve muscle strength and nerve symptoms while avoiding the need for earlier IVIG/SCIG treatment.

Aalborg

Hear when a new CIDP trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.